426 related articles for article (PubMed ID: 37510269)
21. Molecular profiling: an essential technology enabling personalized medicine in breast cancer.
Liu J; Li S; Dunker AK; Uversky VN
Curr Drug Targets; 2012 Apr; 13(4):541-54. PubMed ID: 22250651
[TBL] [Abstract][Full Text] [Related]
22. Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer.
Pavanelli AC; Mangone FR; Barros LRC; Machado-Rugolo J; Capelozzi VL; Nagai MA
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34209776
[TBL] [Abstract][Full Text] [Related]
23. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine.
De Abreu FB; Wells WA; Tsongalis GJ
Am J Pathol; 2013 Oct; 183(4):1075-1083. PubMed ID: 23920325
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-21 in breast cancer: diagnostic and prognostic potential.
Chen J; Wang X
Clin Transl Oncol; 2014 Mar; 16(3):225-33. PubMed ID: 24248894
[TBL] [Abstract][Full Text] [Related]
25. Prognostic and predictive markers for adjuvant therapy.
Schmidt M
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):100-105. PubMed ID: 31833940
[TBL] [Abstract][Full Text] [Related]
26. Genomic predictors of outcome and treatment response in breast cancer.
Dunn L; Demichele A
Mol Diagn Ther; 2009; 13(2):73-90. PubMed ID: 19537843
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.
Cocco S; Piezzo M; Calabrese A; Cianniello D; Caputo R; Lauro VD; Fusco G; Gioia GD; Licenziato M; De Laurentiis M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605126
[TBL] [Abstract][Full Text] [Related]
28. Identification of blood protein biomarkers for breast cancer staging by integrative transcriptome and proteome analyses.
Yao F; Yan C; Zhang Y; Shen L; Zhou D; Ni J
J Proteomics; 2021 Jan; 230():103991. PubMed ID: 32971305
[TBL] [Abstract][Full Text] [Related]
29. Updates on breast biomarkers.
Najjar S; Allison KH
Virchows Arch; 2022 Jan; 480(1):163-176. PubMed ID: 35029776
[TBL] [Abstract][Full Text] [Related]
30. The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer.
Bertoli G; Cava C; Castiglioni I
Scand J Clin Lab Invest Suppl; 2016; 245():S34-9. PubMed ID: 27435502
[TBL] [Abstract][Full Text] [Related]
31. Clinical proteomics and breast cancer.
Zeidan BA; Townsend PA; Garbis SD; Copson E; Cutress RI
Surgeon; 2015 Oct; 13(5):271-8. PubMed ID: 25736469
[TBL] [Abstract][Full Text] [Related]
32. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
33. Available and emerging molecular markers in the clinical management of breast cancer.
Giridhar KV; Liu MC
Expert Rev Mol Diagn; 2019 Oct; 19(10):919-928. PubMed ID: 31498011
[No Abstract] [Full Text] [Related]
34. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
Bownes RJ; Turnbull AK; Martinez-Perez C; Cameron DA; Sims AH; Oikonomidou O
Breast Cancer Res; 2019 Jun; 21(1):73. PubMed ID: 31200764
[TBL] [Abstract][Full Text] [Related]
35. Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
Hahn E; Rodin D; Sutradhar R; Nofech-Mozes S; Trebinjac S; Paszat LF; Rakovitch E
Curr Oncol; 2023 Jun; 30(6):5795-5806. PubMed ID: 37366916
[TBL] [Abstract][Full Text] [Related]
36. Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction.
Kashyap D; Kaur H
Life Sci; 2020 Apr; 246():117417. PubMed ID: 32044304
[TBL] [Abstract][Full Text] [Related]
37. Molecular classification of breast cancer: what the pathologist needs to know.
Rakha EA; Green AR
Pathology; 2017 Feb; 49(2):111-119. PubMed ID: 28040199
[TBL] [Abstract][Full Text] [Related]
38. Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer.
Zhou Q; Ren J; Hou J; Wang G; Ju L; Xiao Y; Gong Y
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2383-2396. PubMed ID: 31280346
[TBL] [Abstract][Full Text] [Related]
39. Microtubule-Associated Protein ATIP3, an Emerging Target for Personalized Medicine in Breast Cancer.
Haykal MM; Rodrigues-Ferreira S; Nahmias C
Cells; 2021 May; 10(5):. PubMed ID: 34062782
[TBL] [Abstract][Full Text] [Related]
40. Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS.
Nofech-Mozes S; Hanna W; Rakovitch E
Am J Pathol; 2019 May; 189(5):975-980. PubMed ID: 30605628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
